Investor082,
Linda won’t be bought out so big pharma takes what they can while they can because the time is coming when the tables turn. They know this, gambled that Linda wouldn’t make it and refused to value this platform correctly early on based on the effort and time needed to make a personalized treatment regimen widely available. This led to undervaluing NWBO as a partner. So fair value was never offered. Linda’s plan is worth waiting for because the science behind it is and that includes ignoring any past low ball offers which those who don’t understand the value of their holdings are still being tempted to accept.
Linda likely has a plan to let the evidence reveal the truth about the platform value at the right time and then the intrinsic value will become quite obvious. The reality is the set up for future success has been put in place now and there will be no piecemeal steps or lack of support after approval at which point the 7 market makers will find themselves at the mercy of a very upset jury and big pharma may be asked by investors why they never got on board more fully early with the safest possible pathway to a cure since their own research showed improved outcomes with DC treatment combo since 2014; ). There might even be a look into any possible relationship between some big hedge funds and big pharma positions they have. Who is going to trust big pharma or their hedge fund buddies to do the right thing if a connection is found there?; ). We already know that NWBO reported a hostile takeover attempt in the past. Best wishes.
Market Data 
Markets 
AI
